Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
k at the full force of our inspectional resources, the FDA is maintaining global vigilance by concentrating inspections on higher risk facilities. As global compliance trends change and standards in some sectors improve we should expect to see an evolution in these trends.

FACT: FDA takes strong compliance and enforcement action when issues are observed

While the numbers of inspections have varied over the past few years, compliance actions, including warning letters, have increased. Warning
23/35 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/19 04:39